Corporate Vision January 2017

74 CORPORATE VISION / January 2017 , Based on Yvonne’s belief that the business could be exploited further, she was sure that she wanted to continue working with Nordic Biosite. Yvonne points out that she began her career in sales, and for several years she worked at Amersham and AMS Biotechnology. “I am still a salesperson at heart, sales is what I do and I am convinced that my background within sales has helped me to expand Nordic Biosite. The ambition and the strategy for this firm has been to build a modern and high quality life science company that can demonstrate strong and stable growth. In order to do this, we have had to back up our ideas with an efficient product/logistic flow, direct from the firm’s headquarters in Stockholm to the end user. We have implemented a modern website which showcases our high quality products and services, and combine distribution with our own services to diversify the business area. “Our number one asset is our people. All members of our sales force have experience in laboratory work, and educational backgrounds ranging from Masters of Science to Ph.Ds. This gives them a unique understanding of our clients’ Leading Light in Life Sciences Around 19 years ago, Yvonne Zar was offered the opportunity to acquire a part of Nordic BioSite AB, which she had been involved in starting. She knew the business well and saw that there was a great potential for the firm’s products and services on the Nordic market. We spoke to Yvonne to find out more about her experience of working in this business and about the future for Nordic Biosite. needs and the ability to offer qualified, relevant help. Information and knowledge is commonly shared within the company and this helps to sustain quality and improvement. We are confident that we can find the product that is right for your research - at the best possible price. Our product range contains products with high quality applications in most research areas, such as Neuroscience, Stem Cell and Cancer Research. “Having been in the business for 20 years, Nordic BioSite is recognized as a leader in the supply of products for research and diagnostic Immunology and Molecular Biology, as well as Pharmaceutical, Biotech, and Diagnostics to academic researchers. Nordic BioSite continuously introduces many unique products as a result of the research and development we undertake with our partners and the feedback we receive from our customers. Through the development, manufacturing, marketing and distribution of our products, our aim is to facilitate your research.” BioSiteHisto optimize and fine- tune antibodies for the needs of the clinical IHC laboratory. Only antibodies that fulfil the criteria of optimal staining pattern are incorporated in our premium product portfolio - Optibodies™. This product line will assist pathologists worldwide with optimal staining resulting in an important diagnostic tool. Optibodies™ is a set of carefully optimized and fine-tuned diagnostically important monoclonal antibodies. The collection is a creation of BioSiteHisto’s immunohistochemistry experts. They are tested and optimized using NordiQC recommendations of control tissues and staining criteria. Only antibodies that reach excellent results in testing protocol and appropriate control tissues are approved as a part of the collection Nordic BioSite, together with its laboratory facility, BioSiteHisto, offers a wide range of custom services. Yvonne explains that these services are fully compliant with international Good Laboratory Practice (GLP) standards and that their mission is to provide services of the highest possible standard to their clients throughout the pharmaceutical and biotechnology industries, including research and diagnostic facilities. “Thanks to our skilled personnel, and because we continue to set high standards for our suppliers, we are able to offer high quality products and services to our clients. We offer a broad range of services and over 2,000,000 products worldwide; whenever and wherever. The products are established within their applications, and we are honoured to say that we help people towards a diagnosis and receiving proper care. “As the CEO, I have been very careful to apply a long-term perspective to our operations, where I look three to five years ahead, as opposed to one year ahead, as I used to as a salesperson. Furthermore, I have been very careful in my search for employees; I recognised early on that the key to a successful business is to have employees with the right skills to drive the company forward and at the same time make them feel valued and satisfied at work. My advice to others in my position is to believe in yourself and your own ideas, to utilise the support of a mentor and to never give up. “The biotechnology industry has become increasingly computerised, like most businesses these days. However, this does not mean that we do not have to be in close contact with our customers, quite the opposite; this is perhaps now even more crucial than prior to the enhancement of technology. “We have established established BioSite offices in Sweden, Finland, Denmark, 1701CV84